SCHEMBL6090347

SCHEMBL6090347

CCC(O)(CC)c1ccc2scnc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 1/20 0.39
LCK P06239 4/20 0.38
RIPK2 O43353 4/20 0.38
KDR P35968 3/20 0.38
TGFBR1 P36897 3/20 0.38
PTK6 Q13882 2/20 0.37
TRPM5 Q9NZQ8 1/20 0.36
FFAR1 O14842 1/20 0.36
ESR1 P03372 1/20 0.36
HSD11B1 P28845 1/20 0.36
TXK P42681 1/20 0.36
SYK P43405 1/20 0.36
ITK Q08881 1/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
KDM4E B2RXH2 1/20 0.35
HKDC1 Q2TB90 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091102 0.87 NPC1 (0.45) ALDH1A1HSD17B10KDRFFAR1ESR1
SCHEMBL14768487 0.82 ALDH1A1 (0.40) ALDH1A1HSD17B10LCKRIPK2KDR
SCHEMBL13265535 0.82 ALDH1A1 (0.40) ALDH1A1HSD17B10LCKRIPK2KDR
SCHEMBL25768089 0.81 ALDH1A1 (0.42) ALDH1A1HSD17B10LCKRIPK2KDR
SCHEMBL761133 0.78 ALDH1A1 (0.45) ALDH1A1HSD17B10LCKRIPK2KDR
SCHEMBL24037602 0.76 ALDH1A1 (0.38) ALDH1A1HSD17B10LCKRIPK2KDR
SCHEMBL23075781 0.76 FFAR1 (0.39) ALDH1A1LCKRIPK2KDRTGFBR1
SCHEMBL22142342 0.75 ALDH1A1 (0.42) ALDH1A1HSD17B10LCKRIPK2KDR
SCHEMBL1538312 0.74 NPC1 (0.47) ALDH1A1HSD17B10ESR1HSD11B1NPC1
SCHEMBL6088891 0.73 HSD17B10 (0.54) ALDH1A1HSD17B10ESR1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060235222-A1 Indole-derivative modulators of steroid hormone nuclear receptors ELI LILLY AND COMPANY (US) 2006-10-19 US disclosed
EP-1597254-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS Eli Lilly and Company (US) 2005-11-23 EP disclosed
WO-2004067529-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS ELI LILLY AND COMPANY (US) 2004-08-12 WO disclosed
WO-2004067529-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS ELI LILLY AND COMPANY (US) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235222-A1 Indole-derivative modulators of steroid hormone nuclear receptors NR3C2, NR5A1, MC2R ALDH1A1 1544/4885HSD17B10 229/4885LCK 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.